These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 7032827

  • 1. The effect of oral prazosin on blood pressure and plasma concentrations of renin and angiotensin II in man.
    McAreavey D, Cumming AM, Sood VP, Leckie BJ, Morton JJ, Murray GD, Robertson JI.
    Clin Sci (Lond); 1981 Dec; 61 Suppl 7():457s-460s. PubMed ID: 7032827
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension.
    van den Meiracker AH, Admiraal PJ, Man in 't Veld AJ, Derkx FH, Ritsema van Eck HJ, Mulder P, van Brummelen P, Schalekamp MA.
    BMJ; 1990 Jul 28; 301(6745):205-10. PubMed ID: 2203486
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prazosin in severe in hypertension effect on blood pressure, plasma renin activity and in hypertensive emergencies.
    Hayes JM.
    Med J Aust; 1977 Aug 27; 2(2 Suppl):30-2. PubMed ID: 916931
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition.
    Atkinson AB, Morton JJ, Brown JJ, Davies DL, Fraser R, Kelly P, Leckie B, Lever AF, Robertson JI.
    Br Heart J; 1980 Sep 27; 44(3):290-6. PubMed ID: 7000102
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Failure of renin suppression by angiotensin II in hypertension.
    Williams GH, Hollenberg NK, Moore TJ, Dluhy RG, Bavli SZ, Solomon HS, Mersey JH.
    Circ Res; 1978 Jan 27; 42(1):46-52. PubMed ID: 618602
    [Abstract] [Full Text] [Related]

  • 14. Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension.
    van den Meiracker AH, Admiraal PJ, Derkx FH, Kleinbloesem C, Man in 't Veld AJ, van Brummelen P, Mulder P, Schalekamp MA.
    J Hypertens; 1993 Aug 27; 11(8):831-8. PubMed ID: 8228207
    [Abstract] [Full Text] [Related]

  • 15. Hormonal and blood pressure responses to tilting in beta-blocked essential hypertension treated with felodipine or prazosin.
    Jackson B, McGrath BP, Johnston CI.
    Drugs; 1987 Aug 27; 34 Suppl 3():87-92. PubMed ID: 2894979
    [Abstract] [Full Text] [Related]

  • 16. Captopril treatment: inter-dose variations in renin, angiotensins I and II, aldosterone and blood pressure.
    Atkinson AB, Cumming AM, Brown JJ, Fraser R, Leckie B, Lever AF, Morton JJ, Robertson JI.
    Br J Clin Pharmacol; 1982 Jun 27; 13(6):855-8. PubMed ID: 7046776
    [Abstract] [Full Text] [Related]

  • 17. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
    Azizi M, Chatellier G, Guyene TT, Murieta-Geoffroy D, Ménard J.
    Circulation; 1995 Aug 15; 92(4):825-34. PubMed ID: 7641363
    [Abstract] [Full Text] [Related]

  • 18. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
    Fridman K, Andersson OK, Wysocki M, Friberg P, Sunzel M.
    Eur J Clin Pharmacol; 1998 Sep 15; 54(7):497-501. PubMed ID: 9832289
    [Abstract] [Full Text] [Related]

  • 19. Evidence of decreased plasma substance P levels in human essential hypertension and influence of prazosin treatment.
    Faulhaber HD, Rathsack R, Rostock G, Homuth V, Pfeiffer D, Naumann E, Hartrodt W, Görne RC, Oehme P.
    Biomed Biochim Acta; 1983 Sep 15; 42(7-8):1019-25. PubMed ID: 6197065
    [Abstract] [Full Text] [Related]

  • 20. Effects of long-term prazosin therapy on lipoprotein metabolism in hypertensive patients.
    Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Hattori N.
    Am J Med; 1984 Feb 27; 76(2A):113-6. PubMed ID: 6367446
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.